QUANTITY – Talk Bio

Merck Advances Middle Dose of ROR1 ADC in Relapsed/Refractory DLBCL After Safety Review

8 months ago talkbio0Tagged Adverse event, Clinical Trials, Diffuse Large B-Cell Lymphoma, Merck, middle dose, Relapsing course, ROR1 protein, human, Safety, therapeutic autologous dendritic cells, Unresponsive to Treatment, vedotin, waveLINE-003, Zilovertamab

Merck; ROR1; ADC; zilovertamab vedotin; middle dose; 1.75 mg/kg; relapsed DLBCL; refractory DLBCL; WaveLINE-003; safety; adverse events; clinical trial; ASCO 2025

Lexicon stumbles on second batch of mixed results for pain drug

11 months ago talkbio0Tagged Dosage, lexicon, Statistical Significance

Dosage, lexicon, Statistical Significance

Eli Lilly makes Zepbound vials cheaper for self-paying patients

11 months ago talkbio0Tagged 10 mg, 7.5 mg, Dosage, Eli, Eli Lilly, Monthly (qualifier value), Prices, self-paying

self-paying, Eli, Eli Lilly, Prices, Monthly (qualifier value), Dosage, 7.5 mg, 10 mg

FDA Greenlights Idorsia’s Aprocitentan (Tryvio) for Resistant Hypertension Patients

2 years ago talkbio0Tagged 12.5 mg, Approved, aprocitentan, aspects of adverse effects, Availability of, Clinical Trials, Combined Modality Therapy, Edema, Endothelin receptor antagonist, Idorsia, Intravascular systolic:Pressure:Point in time:Arterial system:Quantitative, Liquid substance, Precision - temporal, Recommended dosage, Resistant hypertensive disorder, Retention (Psychology), Second Half of 2024, Tryvio, Uncontrolled hypertension, United States Food and Drug Administration

FDA approval, Idorsia, Aprocitentan, Tryvio, Resistant hypertension, Endothelin receptor antagonist, Systolic blood pressure, Uncontrolled hypertension, Combination therapy, Clinical trials, PRECISION study, Recommended dosage: 12.5 mg, Availability: Second half of 2024, Edema and fluid retention side effects